skeleton 1: 293 , 355
structures of 1:290–293
teeth 1: 294 , 358
tendons, ligaments, and fasciae
1: 294
traditions in medical history
1: 295
yoga 4: 106
mutation 4:135
achondroplasia 1: 298
adenocarcinoma 2: 366
albinism 1:135–136
Alzheimer’s disease 1:221–222
birth defects 4: 9
BRCA-1/BRCA-2 2: 369
cancer 2: 364
cerebral palsy 1: 238
CJD 1: 248
CMT disease 1: 317
color deficiency 1: 80
congenital heart disease 2: 38
cystic fibrosis 4: 120
ethical issues in genetics and
molecular medicine 4: 125
genetic carrier 4: 128
genetic disorder 4: 128
genetics and molecular medicine
4: 110
genetic testing 4: 130
Goodpasture’s syndrome 3: 193
hemochromatosis 3: 133
HNPCC 3: 57
Huntington’s disease 1: 256
LQTS 2:74–75
Marfan syndrome 1:335–336
MEN 3: 152
musculoskeletal system 1: 296
myotonic muscular dystrophy
1:337–338
nephritis 3: 207
nervous system 1: 218
neural tube defects 4: 39
oncogenes 2: 384
pemphigus 1: 183
polycystic kidney disease 3: 214
progeria 4: 138
psoriasis 1: 188
Tay-Sachs disease 4: 142
thalassemia 2: 170
tremor disorders 1: 289
tumor suppressor genes 2: 397
vitiligo 1: 208
Wilms’s tumor 3: 232
Wilson’s disease 3: 167
myasthenia gravis 1:339;
2:120–121, 172
Mycobacterium tuberculosis2:269,
305, 359, 360; 4: 49
mydriasis 1:100, 107
myelin 1:255, 263, 270, 317
myelodysplasia syndrome 2:160
myelofibrosis 2:160–161, 164
myeloma 2:275, 283
myocardial cells 2:74–75, 81, 82,
88, 111
myocardial infarction 2:86–87
angina pectoris 2: 12
apoB100 2:16–17
cardiac enzymes 2: 29
cardiomyopathy 2: 32
heart attack 2: 56
heart sounds 2: 60
LVEF 2: 72
sudden cardiac death 2: 108
thrombolytic therapy 2:110, 111
myocardial perfusion imaging 2:87
myocarditis 2: 31 , 87–88, 322
myocardium 2:88, 88 t
angina pectoris 2:11, 12
aorta 2: 16
cardiac enzymes 2: 29
heart 2: 4
medications to treat
cardiovascular disease 2: 79
myocardial infarction 2: 86
myocardial perfusion imaging
2:87
TMLR 2: 112
myoclonus 1:265–266, 266 t
myometrium 3:241, 351
myopathy 1:339–340,350; 4: 134
myopia 1:73, 82, 100–101,111,
113, 114
myotonia 1:340
myotonic muscular dystrophy
1:337–338, 338t
myringitis 1:35
myringotomy 1: 33 , 35,35, 40, 41,
59
myxoma 2:88N
nabothian cyst 3:306
nails 1:177–178, 177 t, 179 , 180
NALT. Seenose-associated lymphoid
tissue
naltrexone 4:320, 325, 344, 354
naphthoquinone. Seevitamin K
narcolepsy 1:267; 4:321, 342
narcotics 1:363, 366, 367, 384;
4:344–345, 345 t. See alsoopiates
dependence 4: 330drugs 4: 145
fentanyl 4: 334
hallucinogens 4: 338
heroin 4: 338
opiates 4: 347
prescription drug abuse 4: 349
substance abuse 4: 311
tolerance 4: 354
narrow therapeutic index (NTI)
2:14–15, 76–78, 81, 83, 375;
4:161–162, 162 t
bioavailability 4: 153
bioequivalence 4: 153
dosage 4: 154
formulary 4: 158
generic drug 4: 159
peak level 4: 168
therapeutic level 4: 172
trough level 4: 173
nasal mucosa 2:243, 319; 4: 328
nasal polyp 1:36
nasal septum 1:49–50
nasal vestibulitis 1:36
nasogastric aspiration and lavage
3:77
National Institutes of Health (NIH)
4:132, 212
Native American healing 4:52, 61,
73, 79, 82–83, 91, 95
natural immunity. Seeinnate
immunity
natural killer (NK) cell 2:151, 236,
253, 268, 272, 276, 278, 286
naturopathy 4:52, 64, 76, 78,
91–92
nausea 3:77–78
nearsightedness. Seemyopia
neck 1:360, 365, 373; 4: 44
necrosis 1:323; 3:20, 83, 347;
4:114, 382
necrotizing fasciitis 2:346, 357
Neisseria gonorrhoeae2:329, 330
neonatal jaundice 1:238; 3: 19 , 306
nephrectomy 3:109, 200, 206–207,
216
nephritis 3:207–208, 224 , 225 , 230
nephroblastoma 3:215, 231
nephrolithiasis 3:208–209
ESWL 3: 189
horseshoe kidney 3:195, 196
hydronephrosis 3: 196
hypercalciuria 3: 196
hyperoxaluria 3: 197
urinary system 3: 173
urolithiasis 3: 227
vesicoureteral reflux 3: 230490 Index